NCT07104240 A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
| NCT ID | NCT07104240 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Human Papillomavirus-Related Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,836 participants |
| Start Date | 2025-05-02 |
| Primary Completion | 2027-03-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,836 participants in total. It began in 2025-05-02 with a primary completion date of 2027-03-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed by the age of 13. It has been estimated that only about 16% of adolescents were fully up to date with HPV vaccines by age 13. Strong and consistent provider recommendations have been shown to play an important role in the uptake of vaccines. In addition, education and information received by parents may improve the strength of recommendations by providers. The TweenVax intervention includes practice, provider, parent and patient level education to teach best practices, help with vaccine messaging, and give correct and easy to understand information to parents. Providing practice, provider and parent level access to TweenVax may be more effective than current vaccine promotion practices in improving HPV vaccination rates in adolescents.
Eligibility Criteria
Inclusion Criteria: * PRACTICE-LEVEL: Must be community based primary care providers (pediatrics or family practice) * PRACTICE-LEVEL: Are willing to be part of the study * PRACTICE-LEVEL: Have sufficient patient population to support 51 adolescents aged 9-12 years over approximately a 9-month period * PRACTICE-LEVEL: Utilize an electronic medical records system and/or report to the state Immunization Information System (IIS) * CHILD/ADOLESCENT: Aged 9-12 years * CHILD/ADOLESCENT: Seeking care from an enrolled practice during the study period * CHILD/ADOLESCENT: Have not received any doses of HPV vaccine by the time of their first visit during the study period
Contact & Investigator
Robert Bednarczyk, PhD
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT07104240 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, studying Human Papillomavirus-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07104240 currently recruiting?
Yes, NCT07104240 is actively recruiting participants. Contact the research team at rbednar@emory.edu for enrollment information.
Where is the NCT07104240 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT07104240 clinical trial?
NCT07104240 is sponsored by Emory University. The principal investigator is Robert Bednarczyk, PhD at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 1,836 participants.